ArticleCytokine2020
Patients with acute respiratory distress syndrome exhibit increased stromelysin1 activity in the blood samples.
Article in Cytokine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 22 citations in OpenAlex.
- Predicting mortality with machine learning & biomarkers: A cohort analysis from aerosolized β₂-agonist for treatment of acute lung injury (ALTA) trial.Physiological reports · 2026Trial
- Plasma matrix metalloproteinase-3 predicts mortality in acute respiratory distress syndrome: a biomarker analysis of a randomized controlled trial.Respiratory research · 2023Trial
- Advanced glycation endproducts induce cytokine dysregulation and weaken lung epithelial and endothelial barrier integrity.Tissue barriers · 2026Article
- Early detection of lung injury and matrix metalloproteinase activation in ARDS could improve diagnostic and therapeutic strategies?Expert review of respiratory medicine · 2025Article
- Claudin-17 Deficiency Drives Vascular Permeability and Inflammation Causing Lung Injury.International journal of molecular sciences · 2025Article
- Article
- MMP3 in Severe COVID-19: A Biomarker or Therapeutic Target?Infectious disorders drug targets · 2023Article
- Cisatracurium attenuates LPS-induced modulation of MMP3 and junctional protein expression in human microvascular endothelial cells.Bioscience trends · 2021Article
- Cell-cell junctions: structure and regulation in physiology and pathology.Tissue barriers · 2021Review
- Pharmacological Inhibition of MMP3 as a Potential Therapeutic Option for COVID-19 Associated Acute Respiratory Distress Syndrome.Infectious disorders drug targets · 2021Article
- Expression Level, Correlation, and Diagnostic Value of Serum miR-127 in Patients with Acute Respiratory Distress Syndrome.Evidence-based complementary and alternative medicine : eCAM · 2021Article
- Regulation of blood-retinal barrier cell-junctions in diabetic retinopathy.Pharmacological research · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 1 institution in 1 country.
Funding
Abstract
Enzyme activity analyses in the blood are expected to be reliable, non-invasive diagnostic as well as prognostic markers to reflect disease progression in acute lung injury (ALI). The objective of the current study was to evaluate the enzymatic activity of stromelysin1 (matrix metalloprotease-3) in the plasma/serum samples collected from ALI patients compared to the samples collected from healthy controls. Gene expression omnibus (GEO) database analysis indicated a correlation between increased stromelysin1 gene expression and the incidence of ALI in various animal models. Our analysis of patient plasma/serum samples from healthy controls and ALI patients revealed a significant, 3-fold increase in stromelysin1 activity in ALI plasma/serum compared to healthy subjects with no difference in stromelysin1 activity between the serum and plasma samples. Interestingly, no significant difference in stromelysin1 activity between non-smoking and smoking subjects was observed. These findings provide fundamental information on the potential reliability of stromelysin1 activity analysis, combined with other biomarkers in development, in blood samples for the early detection of ALI.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.